Antibody surrogates for therapeutics, in vivo imaging,
and in vitro diagnostics

Peptide-.png
IndiMolecular.jpg

Antibody surrogates for
therapeutics, in vivo imaging,
and in vitro diagnostics

Peptide-.png
IndiMolecular.jpg

 Antibody surrogates for
therapeutics, in vivo imaging,
and in vitro diagnostics

Peptide.png
IndiMolecular.jpg
 

Indi Molecular is developing protein catalyzed capture agents (PCCs) as a small molecule replacement for antibodies in therapeutics, in vivo imaging, and in vitro diagnostics. The PCC platform allows us to build fully synthetic small peptides against specific epitopes of the desired target protein. Affinity and specificity are equivalent or superior to monoclonal antibodies.

We’ve achieved picomolar binding affinities. PCCs are the synthetic equivalent of monoclonal antibodies, offering the small size (< 4 kD) and biophysical properties of a small molecule drug.

 
 
 
key.png

Specificity

Specific to the chosen epitope of the desired target protein

magnet.png

Affinity

Pico-molar and low nano-molar binding affinities

settings@2x.png

Developable

Fully synthetic small peptides for rapid and robust manufacturing

 

Recent News